Evidence map›Paper›PMID 30879076›Full record

Trial reportNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2020

Contribution of 'clinically negligible' residual kidney function to clearance of uremic solutes.

Stephanie M Toth-Manikowski, Tammy L Sirich, Timothy W Meyer, Thomas H Hostetter, Seungyoung Hwang, Natalie S Plummer, Xin Hai, Josef Coresh, Neil R Powe, Tariq Shafi

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05105009 (Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05105009 phase1completednot on this map

Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function: is It Better Than GFR?

TypeinterventionalSponsorInstituto Nacional de Cardiologia Ignacio ChavezRan2020 to 2024Enrolled50ConditionsChronic Kidney FailureArmsFurosemide Injection, Creatinine Powder, Iohexol
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Twice Weekly versus Thrice Weekly Hemodialysis-A Pilot Cross-Over Equivalence Trial.Clinical journal of the American Society of Nephrology : CJASN · 2024
    Article
  10. Review
  11. Article
  12. Delayed Graft Function After Kidney Transplantation: The Role of Residual Diuresis and Waste Products, as Oxalic Acid and Its Precursors.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Narrative Review of Incremental Hemodialysis.Kidney international reports · 2020
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Stephanie M Toth-ManikowskiDepartment of Medicine, Division of Nephrology, University of Illinois at Chicago, Chicago, IL, USA.
Tammy L SirichDepartment of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Timothy W MeyerDepartment of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Thomas H HostetterDepartment of Medicine, Palo Alto Veterans Affairs Health Care System, Stanford University, Palo Alto, CA, USA.
Seungyoung HwangDepartment of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Natalie S PlummerDepartment of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Xin HaiDepartment of Medicine, Palo Alto Veterans Affairs Health Care System, Stanford University, Palo Alto, CA, USA.
Josef CoreshDepartment of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Neil R PoweDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Tariq ShafiDepartment of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USVA Palo Alto Health Care System · USSan Francisco General Hospital · USUniversity of Illinois Chicago · US

Funding

Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Hopkins Clinical CenterU01DK061022 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI APPEL, LAWRENCE JOHN · 2001 to 2025
$15.7M
RENAL DISEASE EPIDEMIOLOGY TRAINING GRANTT32DK007732 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CREWS, DEIDRA CANDICE · 1995 to 2024
$7.7M
ConProject-001UH3AG056933 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J., VARADHAN, RAVI · 2019 to 2021
$7.0M
Dietary and Microbial Reprogramming of Intestinal Microbiota-Produced MetabolitesR01DK101674 · NIDDK · STANFORD UNIVERSITY · PI FISCHBACH, MICHAEL ANDREW, MEYER, TIMOTHY W · 2014 to 2024
$6.5M
Characterizing Resiliencies to Physical Stressors in Older Adults: A Dynamical Physiological Systems ApproachUH2AG056933 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J., VARADHAN, RAVI · 2017 to 2018
$3.5M
CAMARO-ESRD: Cardiac Arrhythmia Monitoring and Related Outcomes in End Stage Renal Disease PatientsR01HL132372 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GUALLAR, ELISEO, SHAFI, TARIQ · 2017 to 2019
$2.3M
Identification of CKD and CVD BiomarkersU01DK106965 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI BRUNENGRABER, HENRI, HOSTETTER, THOMAS HEARD · 2015 to 2019
$1.6M
Volume Management in Dialysis Patients Guided by Pulse Amplitude RationR03DK104012 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SHAFI, TARIQ · 2015 to 2016
$151k
New Solutes to Assess Kidney DiseaseIK2CX001036 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI SIRICH, TAMMY LISA · 2014 to 2018
–
CSRD VA IK2 CX001036NHLBI NIH HHS R01 HL132372NIA NIH HHS UH2 AG056933NIA NIH HHS UH3 AG056933NIDDK NIH HHS R01 DK101674NIDDK NIH HHS R03 DK104012NIDDK NIH HHS T32 DK007732NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK106965
6 · The paper itself

Abstract

backgroundResidual kidney function (RKF) is thought to exert beneficial effects through clearance of uremic toxins. However, the level of native kidney function where clearance becomes negligible is not known.

methodsWe aimed to assess whether levels of nonurea solutes differed among patients with 'clinically negligible' RKF compared with those with no RKF. The hemodialysis study excluded patients with urinary urea clearance >1.5 mL/min, below which RKF was considered to be 'clinically negligible'. We measured eight nonurea solutes from 1280 patients participating in this study and calculated the relative difference in solute levels among patients with and without RKF based on measured urinary urea clearance.

resultsThe mean age of the participants was 57 years and 57% were female. At baseline, 34% of the included participants had clinically negligible RKF (mean 0.7 ± 0.4 mL/min) and 66% had no RKF. Seven of the eight nonurea solute levels measured were significantly lower in patients with RKF than in those without RKF, ranging from -24% [95% confidence interval (CI) -31 to -16] for hippurate, -7% (-14 to -1) for trimethylamine-N-oxide and -4% (-6 to -1) for asymmetric dimethylarginine. The effect of RKF on plasma levels was comparable or more pronounced than that achieved with a 31% higher dialysis dose (spKt/Vurea 1.7 versus 1.3). Preserved RKF at 1-year follow-up was associated with a lower risk of cardiac death and first cardiovascular event.

conclusionsEven at very low levels, RKF is not 'negligible', as it continues to provide nonurea solute clearance. Management of patients with RKF should consider these differences.

Indexed as

FemaleHumansKidneyKidney Failure, ChronicKidney Function TestsMaleMiddle AgedRenal DialysisUreaUreaclearancedialysis doseESRDhemodialysisuremic toxins

Identifiers

PMID30879076
PMCPMC7203561
OpenAlexW2921014173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.